Protocol Ledger

NCT05555615 · Phase II/III · TERMINATED

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Interventional Phase II/III clinical trial protocol NCT05555615 sponsored by ACADIA Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-02 Enrollment: 209 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05555615
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)209 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05555615
Protocol FieldVerified Registry Value
NCT IdentifierNCT05555615
Consolidated Lead SponsorACADIA Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment209 participants (ACTUAL)
Registered Start Date2022-11-02
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05555615
Hospital Research SiteLocationSite Profile
Cincinnati Children's Hospital Medical CenterCincinnati, OHOpen Hospital Dossier ->
Children's Hospital of PhiladelphiaPhiladelphia, PAOpen Hospital Dossier ->
Medical University of South CarolinaCharleston, SCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI